All Updates

All Updates

icon
Filter
Partnerships
METiS Therapeutics enters into licensing agreement with Voronoi
AI Drug Discovery
Sep 13, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Sep 13, 2022

METiS Therapeutics enters into licensing agreement with Voronoi

Partnerships

  • Massachusetts-based AI drug discovery company METiS Therapeutics entered into a licensing agreement with Korean precision medicine company Voronoi. The terms and financial details of the agreement have not been disclosed.

  • Through the agreement, METiS will receive an exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program worldwide, in exchange for USD 1.7 million in upfront payment and up to USD 480.5 million upon achieving certain milestones. 

  • The pan-RAF inhibitor program will focus on treating Class II and Class III BRAF (an oncogene that promotes cancerous cell growth if mutated) mutant cancers, especially central nervous system (CNS) metastases. It will also contribute to scaling the company’s AiTEM platform with enhanced capabilities.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.